Is Indonesia the Fastest Country for Medical Device Approval Among the World’s Most Populous Nations?

Medical device registration in Indonesia takes just 40 working days for Class A products, and 60 working days for Class B, C, and D products. Compared with the review timelines in Europe, the United States, and China, some of which stretch past two years, that’s a remarkably fast turnaround.

To understand exactly how Indonesia stacks up, we compared medical device approval timelines across the world’s ten most populous regulatory markets, nine countries plus the European Union as a single regulatory bloc. The results put Indonesia in a genuinely striking position.

1. Introduction

It might seem surprising that Indonesia ranks among the fastest countries for medical device approval. In day-to-day practice, working with Indonesian government agencies isn’t always straightforward. Yet when it comes to the formal medical device registration timeline itself, the numbers tell a clear story: Indonesia’s process is fast, statutory, and predictable, especially compared to markets many times its size.

This comparison covers the ten most populous regulatory units in the world by population: India, China, the European Union (27 member states combined under EU MDR), the United States, Indonesia, Pakistan, Nigeria, Brazil, Bangladesh, and Russia.

2. Indonesia’s Medical Device Approval Timeline

Indonesia’s medical device registration process runs through Kemenkes (Ministry of Health) and BPOM, and unlike many of the countries in this comparison, it operates on an official, statutory timeline defined in working days.

There’s applicant preparation time for supplementary documents between the two review stages, and typically up to one or two rounds of supplementary requests. Even accounting for that, a 40- to 60-day total stands out as an exceptionally fast, and officially defined, turnaround.

3. How the World’s 10 Most Populous Regulators Compare

Ranked by population, here’s how each market’s representative total timeline for medium-risk devices compares, along with whether that timeline is backed by an official statutory deadline or is a practical, industry-estimated range.

Among the top five most populous markets, Indonesia is the only one with a total timeline measured in weeks rather than months or years, and one of only a few anywhere on this list with a clearly defined, officially statutory deadline that businesses can actually plan around.

4. Closer Look: India, China, the EU, and the US

India (CDSCO)

India has no unified, official class-by-class SLA. Class A devices go through self-registration via an accredited testing lab, roughly 90–180 days. Class B review runs around 140 days (expected to shorten to about 115 days once a pending 2026 amendment takes effect), while Class C/D review runs about 105 days, though the import license itself carries a statutory 9-month cap. Total timelines range from 90–270 days for Class B to 180–450 days for Class C/D, including import procedures, with typically 2–4 rounds of supplementary data requests in practice.

China (NMPA / CMDE)

China’s official review periods look deceptively short on paper, Class II review takes roughly 90–100 working days and Class III around 120–130 working days, but these figures cover only CMDE’s pure review time. Once clinical trial review and expert consultation are factored in, practical total timelines stretch to 12–24 months for Class II and 24–36 months for Class III (up to 60 months where clinical trials are required).

Europe (EU MDR / Notified Body)

Under EU MDR, Class I devices (non-sterile, non-measuring) require no Notified Body involvement at all, just manufacturer self-declaration. From there, timelines climb quickly: Class IIa averages 6–9 months, Class IIb runs 8–18 months, and Class III or implantable devices take 12–24 months in practice. Since MDR took effect in 2021, stricter clinical-evidence requirements and Notified Body capacity shortages have roughly doubled timelines compared to the previous MDD framework. Applications submitted in 2026 reportedly aren’t completing review until mid-to-late 2027. The EU’s first binding review-time caps only take effect February 25, 2027, and even then, exceeding them won’t obligate a Notified Body to issue a certificate.

United States (FDA / CDRH)

The FDA’s MDUFA goals suggest fast review, 90 FDA-days for 510(k) submissions, 180 FDA-days for PMA, but “FDA days” count only active review time and exclude Additional Information hold periods. Real-world averages tell a different story: 510(k) submissions average 140–210 days, while PMA submissions average 1,013 days, roughly 2.8 years, partly due to a post-2020 review backlog pushing timelines to more than 3x the official goal.

5. Why Statutory Timelines and Real-World Timelines Diverge

Across nearly every market in this comparison, there’s a meaningful gap between the officially stated review period and the practical, real-world timeline. Brazil, Russia, China, the US (for PMA), and Europe all run parallel procedures, facility inspections, clinical trials, GMP certification, Notified Body review, that sit outside the core “review period” itself, which is exactly why total timelines run far longer than the headline figures suggest.

India, Pakistan, Nigeria, and Bangladesh have no officially published class-by-class SLA at all, meaning their figures come entirely from consulting-firm practical experience rather than binding regulation. The EU, similarly, has no binding official cap until February 2027.

6. Indonesia’s Medical Device Market Is Growing Fast

Speed of approval matters more when the underlying market is worth entering quickly. Indonesia’s medical device market is projected to grow at roughly 9% per year.

Combine a market growing at roughly 9% annually with a registration process that takes weeks rather than years, and the opportunity for foreign medical device manufacturers becomes hard to ignore.

7. What This Means for Foreign Medical Device Companies

For manufacturers weighing where to prioritize market entry, Indonesia’s combination of speed and growth changes the calculus in a few concrete ways.

• Faster time-to-revenue — a 40- to 60-day registration window means products can reach the Indonesian market while competitors are still mid-review in slower jurisdictions
• More reliable planning — because Indonesia’s statutory and real-world timelines closely match, launch planning and inventory decisions can be built around a dependable date, not a wide estimate range
• Lower regulatory overhead relative to market size — Indonesia offers a fast, predictable process without the multi-year clinical and Notified Body procedures required in the EU or US for higher-risk devices
• A genuine first-mover window — with the market itself growing around 9% per year, faster registration means more time capturing share before the category matures

8. Conclusion

Among the world’s ten most populous regulatory markets, Indonesia offers one of the fastest, and one of the only genuinely statutory, medical device approval timelines, 40 working days for Class A devices and 60 working days for Class B, C, and D devices. That places it well ahead of far larger markets like China, the EU, and the US, where official goals are frequently dwarfed by real-world review times stretching into years.

Paired with a medical device market growing at roughly 9% annually, Indonesia represents a genuine opportunity for manufacturers willing to move early, provided the registration dossier, Local Representative arrangement, and supporting certifications are prepared correctly from day one.

Frequently Asked Questions